Drugs / IMA101
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02876510 | Jun 2017 → Sep 2021 | cancer | Immatics US, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMA101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02876510 ↗ |
| Route | Intravenous | “i.v. infusion of IMA101 product(s).” NCT02876510 ↗ |